Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Sandler

Showing results (11-20 of 90) with videos related to

Pageof 9
Sort By:
Clinical Orthopaedics and Related Research|April 16, 2002
Karnofsky performance score as a predictor of survival in soft tissue sarcomaBruce Rougraff, Alan Sandler
Clinical Lung Cancer|March 27, 2007
Chemotherapy and antiangiogenic agents in non-small-cell lung cancerLeora Horn, Alan Sandler
Current Problems in Cancer|May 29, 2012
Systemic issues in small cell lung cancerAriel Lopez-Chavez, Alan Sandler
The Oncologist|November 11, 2008
Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLCRoy S Herbst, Alan Sandler
Clinical Advances in Hematology & Oncology : H&O|December 5, 2006
Angiogenesis inhibition in the treatment of lung cancerEverett Vokes, Roy Herbst, Alan Sandler
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2005
Angiogenesis and lung cancer: prognostic and therapeutic implicationsRoy S Herbst, Amir Onn, Alan Sandler
Journal of the National Cancer Institute|August 7, 2003
An advance in small-cell lung cancer treatment--more or lessJanessa Laskin, Alan Sandler, David H Johnson
Current Opinion in Chemical Biology|June 11, 2018
Recent progress in therapeutic antibodies for cancer immunotherapyAnthony Lee, Shawn Sun, Alan Sandler, et al.
Lung Cancer (Amsterdam, Netherlands)|October 9, 2002
Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC. A Hoosier Oncology Group (HOG) phase II studySumeet Bhatia, Nasser Hanna, Rafat Ansari, et al.
BMC Cancer|July 15, 2016
Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validationKelong Han, Laurent Claret, Alan Sandler, et al.
Pageof 9

Showing results (11-20 of 90) with videos related to

Sort By:
Pageof 9
Clinical Orthopaedics and Related Research|April 16, 2002
Karnofsky performance score as a predictor of survival in soft tissue sarcomaBruce Rougraff, Alan Sandler
Clinical Lung Cancer|March 27, 2007
Chemotherapy and antiangiogenic agents in non-small-cell lung cancerLeora Horn, Alan Sandler
Current Problems in Cancer|May 29, 2012
Systemic issues in small cell lung cancerAriel Lopez-Chavez, Alan Sandler
The Oncologist|November 11, 2008
Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLCRoy S Herbst, Alan Sandler
Clinical Advances in Hematology & Oncology : H&O|December 5, 2006
Angiogenesis inhibition in the treatment of lung cancerEverett Vokes, Roy Herbst, Alan Sandler
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2005
Angiogenesis and lung cancer: prognostic and therapeutic implicationsRoy S Herbst, Amir Onn, Alan Sandler
Journal of the National Cancer Institute|August 7, 2003
An advance in small-cell lung cancer treatment--more or lessJanessa Laskin, Alan Sandler, David H Johnson
Current Opinion in Chemical Biology|June 11, 2018
Recent progress in therapeutic antibodies for cancer immunotherapyAnthony Lee, Shawn Sun, Alan Sandler, et al.
Lung Cancer (Amsterdam, Netherlands)|October 9, 2002
Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC. A Hoosier Oncology Group (HOG) phase II studySumeet Bhatia, Nasser Hanna, Rafat Ansari, et al.
BMC Cancer|July 15, 2016
Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validationKelong Han, Laurent Claret, Alan Sandler, et al.
Pageof 9